Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Income from Continuing Operations (2017 - 2025)

Dianthus Therapeutics has reported Income from Continuing Operations over the past 8 years, most recently at 38941000.0 for Q3 2025.

  • Quarterly results put Income from Continuing Operations at 38941000.0 for Q3 2025, down 40.1% from a year ago — trailing twelve months through Sep 2025 was 127493000.0 (down 72.82% YoY), and the annual figure for FY2024 was 84499000.0, down 94.65%.
  • Income from Continuing Operations for Q3 2025 was 38941000.0 at Dianthus Therapeutics, down from 34521000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for DNTH hit a ceiling of 28208000.0 in Q4 2022 and a floor of 38941000.0 in Q3 2025.
  • Median Income from Continuing Operations over the past 4 years was 17918000.0 (2024), compared with a mean of 16761333.33.
  • Peak annual rise in Income from Continuing Operations hit 69.16% in 2023, while the deepest fall reached 149.33% in 2023.
  • Dianthus Therapeutics' Income from Continuing Operations stood at 28208000.0 in 2022, then crashed by 149.33% to 13916000.0 in 2023, then crashed by 77.1% to 24645000.0 in 2024, then tumbled by 58.01% to 38941000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 38941000.0 (Q3 2025), 34521000.0 (Q2 2025), and 29386000.0 (Q1 2025) per Business Quant data.